Literature DB >> 27308019

Novel GluN2B selective NMDA receptor antagonists: relative configuration of 7-meth-oxy-2-methyl-2,3,4,5-tetra-hydro-1H-3-benzazepin-1-ols.

Bastian Tewes1, Bastian Frehland1, Roland Fröhlich2, Bernhard Wünsch3.   

Abstract

The title compounds, C22H29NO2 (3) and C22H29NO2 (4) [systematic names: (1S*,2R*)-7-meth-oxy-2-methyl-3-(4-phenyl-but-yl)-2,3,4,5-tetra-hydro-1H-3-benzazepin-1-ol and (1R*,2R*)-7-meth-oxy-2-methyl-3-(4-phenyl-but-yl)-2,3,4,5-tetra-hydro-1H-3-benzazepin-1-ol, are diastereomers with the relative configuration of the adjacent hydroxyl and methyl groups at the seven-membered azepine ring being trans in (3) and cis in (4). In the crystals the orientation of these groups is -anti-periplanar (3) and +syn-clinal (4). In both cases, the crystals studied proved to be of a racemic mixture, with relative configurations (R*,S*)-3 and (R*,R*)-4. In both compounds, the seven-membered azepine ring has a chair-like conformation, and the 4-phenyl-butyl side chain adopts a extended conformation in (R*,S*)-3, but a twisted conformation in (R*,R*)-4. In the crystal of (S*,R*)-3, mol-ecules are linked via C-H⋯O hydrogen bonds, forming slabs parallel to the ac plane. In the crystal of (R*,R*)-4, mol-ecules are linked via O-H⋯N hydrogen bonds, forming chains propagating along the c-axis direction. The chains are linked by C-H⋯O hydrogen bonds, forming slabs parallel to the ac plane.

Entities:  

Keywords:  GluN2B antagonists; NMDA receptor antagonists; conformational restriction; crystal structure; ifenprodil analogs; relative configuration; tetra­hydro-3-benzazepines

Year:  2016        PMID: 27308019      PMCID: PMC4908524          DOI: 10.1107/S2056989016005843

Source DB:  PubMed          Journal:  Acta Crystallogr E Crystallogr Commun


  16 in total

1.  Multiparametric scaling of diffraction intensities.

Authors:  Zbyszek Otwinowski; Dominika Borek; Wladyslaw Majewski; Wladek Minor
Journal:  Acta Crystallogr A       Date:  2003-04-25       Impact factor: 2.290

Review 2.  Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Authors:  James N C Kew; John A Kemp
Journal:  Psychopharmacology (Berl)       Date:  2005-02-25       Impact factor: 4.530

Review 3.  NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore.

Authors:  István Borza; György Domány
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

4.  Design, Synthesis, and Biological Evaluation of 3-Benzazepin-1-ols as NR2B-Selective NMDA Receptor Antagonists.

Authors:  Bastian Tewes; Bastian Frehland; Dirk Schepmann; Kai-Uwe Schmidtke; Thomas Winckler; Bernhard Wünsch
Journal:  ChemMedChem       Date:  2010-05-03       Impact factor: 3.466

Review 5.  Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action.

Authors:  K Williams
Journal:  Curr Drug Targets       Date:  2001-09       Impact factor: 3.465

6.  Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.

Authors:  Bastian Tewes; Bastian Frehland; Dirk Schepmann; Kai-Uwe Schmidtke; Thomas Winckler; Bernhard Wünsch
Journal:  Bioorg Med Chem       Date:  2010-09-24       Impact factor: 3.641

7.  Metabolism studies of ifenprodil, a potent GluN2B receptor antagonist.

Authors:  Evamaria Falck; Frank Begrow; Eugen Verspohl; Bernhard Wünsch
Journal:  J Pharm Biomed Anal       Date:  2013-08-21       Impact factor: 3.935

Review 8.  Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain.

Authors:  Long-Jun Wu; Min Zhuo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

9.  Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors.

Authors:  Erkan Karakas; Noriko Simorowski; Hiro Furukawa
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

10.  Structure validation in chemical crystallography.

Authors:  Anthony L Spek
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.